Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02628535
Other study ID # CP-MGD009-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 2015
Est. completion date November 25, 2019

Study information

Verified date February 2022
Source MacroGenics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.


Description:

This study is a Phase 1 open-label, dose escalation, cohort expansion, and efficacy follow-up study of MGD009 administered intravenously (IV) on an every-other-week schedule for up to one year (14 cycles). The dose escalation phase is designed to characterize the safety and tolerability of MGD009 and to define the maximum tolerated or maximum administered dose (MTD/MAD). This phase will enroll patients with mesothelioma, bladder cancer, melanoma, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), ovarian cancer, thyroid cancer, triple-negative breast cancer (TNBC), pancreatic cancer, colon cancer, soft tissue sarcoma, or prostate cancer. In the cohort expansion phase, 6 cohorts of 16 patients each will be enrolled to further evaluate the safety and potential efficacy of MGD009 administered at the MTD/MAD dose in patients with mesothelioma, bladder cancer, melanoma, SCCHN, NSCLC, or other specific tumors that express high levels of B7-H3. Pre- and on-study biopsies are required for melanoma patients in the cohort expansion phase. Two additional cohorts (up to15 patients each) will evaluate the use of prophylaxis therapies to mitigate toxicity. The survival follow-up phase consists of the 2-year period after the final dose of study drug. All tumor evaluations will be carried out by both Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC).


Recruitment information / eligibility

Status Terminated
Enrollment 67
Est. completion date November 25, 2019
Est. primary completion date November 25, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically and/or cytologically proven unresectable locally advanced or metastatic tumors that express B7-H3 on the membrane or vasculature. The requirement for previous systemic therapy may be waived if a person was intolerant of standard front-line therapy - Dose escalation phase prior systemic treatment requirements: - pleural mesothelioma, pancreatic cancer: 1-3 prior treatments - urothelial, SCHNN, prostate, soft tissue sarcoma, prostate cancer, TNBC, ccRCC, NSCLC: 1-5 prior treatments - ovarian cancer: 2-4 prior treatments - colon cancer: 2-4 prior treatments - cutaneous melanoma: at least 1 prior treatment (including immunotherapy). - Patients with prior immune checkpoint inhibitors must have related toxicities reduced to Grade 0, 1, or baseline - Measurable disease per RECIST 1.1 criteria - Easter Cooperative Oncology Group (ECOG) performance status 0 or 1 - Acceptable laboratory parameters and adequate organ reserve. Exclusion Criteria: - Patients with central nervous system (CNS) involvement must have been treated, be asymptomatic, do not exhibit progression of CNS metastases on MRI or CT within 28 days, and do not have concurrent leptomeningeal disease or cord compression. - Clinically significant pulmonary compromise within 28 days of first dose, including pneumonia, pneumonitis, requirement for supplemental oxygen). use to maintain adequate oxygenation, or pleural effusion sufficient to warrant pleurocentesis or any history of = Grade 3 drug induced or radiation pneumonitis. - History of autoimmune disease with certain exceptions such as vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within the past 2 years, patients with history of Hashimoto's or Grave's disease that are now euthyroid clinically and by lab testing - History of clinically-significant cardiovascular disease, or cardiac arrhythmias, including atrial fibrillation at screening or day of treatment - History of clinically-significant gastrointestinal (GI) disease; GI perforation within 1 year; GI bleeding or acute pancreatitis within 3 months; or diverticulitis within 4 weeks of first study drug administration - Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration - Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction (PCR) - Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome - History of allogeneic bone marrow, stem cell, or solid organ transplant - Treatment with systemic cancer therapy or investigational therapy within 3 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration - Trauma or major surgery within 4 weeks of first study drug administration - Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009

Study Design


Intervention

Biological:
MGD009
B7-H3 x CD3 DART protein

Locations

Country Name City State
Australia Chris O'Brien Lifehouse Camperdown New South Wales
Australia Saint Vincent's Hospital Sydney Darlinghurst New South Wales
Australia Austin Health Heidelberg Victoria
Australia Linear Clinical Research Nedlands Western Australia
Australia Princess Alexandra Hospital Woolloongabba Queensland
Canada Princess Margaret Cancer Centre Toronto Ontario
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Mary Crowley Cancer Research Center Dallas Texas
United States Virginia Cancer Specialists Fairfax Virginia
United States Carolina BioOncology Institute Huntersville North Carolina
United States UCLA Los Angeles California
United States Henry-Joyce Cancer Center Nashville Tennessee
United States Columbia University Medical Center New York New York
United States New York University New York New York
United States Stanford University School of Medicine Palo Alto California
United States Penn Presbyterian Medical Center Philadelphia Pennsylvania
United States South Texas Accelerated Research Therapeutics, LLC San Antonio Texas
United States University of California - San Francisco San Francisco California
United States Georgetown University Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
MacroGenics

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events adverse events, serious adverse events 28 days after last dose of study drug
Secondary Peak plasma concentration PK of MGD009 8 days
Secondary Number of participants that develop anti-drug antibodies Proportion of patients who develop anti-MGD0009 antibodies, immunogenicity first dose through 28 days after last dose of study drug
Secondary Change in tumor volume Anti-tumor activity of MGD009 using both conventional RECIST 1.1 and immune-related RECIST criteria. Weeks 6, 15, 24, 33, 42, 51, 60, 69, 78, 87, 96, 105
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A